TFFP Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

Stats
Today's Volume	3 626.00
Average Volume	30 241.00
Market Cap	7.83M
EPS	$0 ( 2024-04-02 )
Next earnings date	( $-2.20 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.260
ATR14	$0.0480 (1.54%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-13	King Thomas Braxton	Buy	132 442	Stock Options (Right to Buy)
2023-12-11	King Thomas Braxton	Buy	0
2023-12-01	Roberts Brandi	Buy	52 858	Stock Options (Right to Buy)
2023-12-01	Mills Robert S	Buy	52 858	Stock Options (Right to Buy)
2023-12-01	Rocamboli Stephen	Buy	52 858	Stock Options (Right to Buy)

INSIDER POWER
69.74
Last 95 transactions
Buy: 4 763 088 \| Sell: 2 981 910

TFF Pharmaceuticals Inc Correlation

10 Most Positive Correlations
MRACW	0.954
BIOL	0.949
NRBO	0.946
RMRM	0.942
KBSF	0.94
SLNH	0.939
GRNV	0.935
AVCT	0.934
AYLA	0.929
TDAC	0.927

10 Most Negative Correlations
VLYPO	-0.938
BOCH	-0.931
IART	-0.923
SLGN	-0.92
MMAC	-0.919
RFEU	-0.919
LMRK	-0.918
INNV	-0.917
LOPE	-0.914
AGFS	-0.911

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

TFF Pharmaceuticals Inc Financials

Annual	2023
Revenue:	$733 871
Gross Profit:	$231 391 (31.53 %)
EPS:	$-11.85

Q4	2023
Revenue:	$0
Gross Profit:	$-130 666 (0.00 %)
EPS:	$-2.01

Q3	2023
Revenue:	$0
Gross Profit:	$-125 119 (0.00 %)
EPS:	$-2.32

Q2	2023
Revenue:	$0
Gross Profit:	$-123 528 (0.00 %)
EPS:	$-3.47

Financial Reports:

No articles found.

TFF Pharmaceuticals Inc

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's lead drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as cannabidiol substance for the treatment of various epilepsy syndromes, as well as anxiety, insomnia, and various pain; Inhaled SARS-CoV2 Monoclonal Antibody for the treatment of patients with COVID-19 infections; Niclosamide Inhalation Powder to treat tapeworm infections in humans, as well as COVID-19 disease; and other vaccines. The company has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop inhaled SARS-CoV2 monoclonal antibody; and a licensing and collaboration agreement with UNION therapeutics A/S. The company was incorporated in 2018 and is based in Austin, Texas.